Wednesday, 19 Feb 2020

You are here

Fewer Lupus Flares on Low Dose Steroids

French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.

This one year, open-label, trial compared outcomes of 61 SLE patients continuing 5 mg/day prednisone and 63 stopping it. The primary endpoint was the proportion of patient experiencing a flare defined with the SELENA-SLEDAI flare index (SFI) at 52 weeks.

Those who maintained low dose prednisone had significantly fewer flares compared with the withdrawal group (4 vs 17; RR 0.2 (95% CI 0.1 to 0.7), p=0.003).

Time to first flare was also lower in the maintenance 5 mg prednisone group (HR 0.2; 95% CI 0.1 to 0.6, p=0.002).

Adverse events were similar in the two treatment groups.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

BSR Guidelines for Giant Cell Arteritis

NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.

PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV

The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.

Shingles Vaccine Lowers Risk of CVA

Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.

EULAR Recommendations on Sjögren’s Syndrome

The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.